A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neurone disease (MND). It affects the nerve cells responsible for controlling muscles. This clinical trial, named AURORA, is testing an experimental drug called siplizumab in adults who have recently been diagnosed with ALS. Because this is an early-stage study (Phase 1), the main goal is safety. Researchers need to see how well the body handles the drug and check for any side effects. They will also measure how the medicine moves through the body and how it affects certain immune cells. Participants take part for 52 weeks (around one year). During this time, they receive the study medicine and attend regular clinic visits for health checks, nerve assessments, and blood tests. This trial helps doctors decide whether siplizumab should be tested in larger studies in the future.
Överblick
Vad handlar denna studie om?
Amyotrophic lateral sclerosis, often called ALS, is a condition that affects the nerves in the brain and spinal cord. In the UK, it is often referred to under the wider umbrella of motor neurone disease (MND). Over time, these nerves stop working properly, which makes everyday activities like walking, speaking, and swallowing difficult. Finding new treatments that can slow down or stop this nerve damage is an urgent priority for researchers.
Scientists believe that the immune system, which usually protects us from illness, might play a role in harming nerve cells in people with ALS. The AURORA study is testing an experimental drug called siplizumab. Siplizumab is designed to interact with specific immune cells, with the aim of calming down harmful immune activity.
This is a Phase 1 study, which means it is one of the earliest steps in testing a medicine in humans. The trial focuses on people who have received an ALS diagnosis relatively recently. The main purpose is not yet to prove how well the medicine works against the disease, but to make sure it is safe to use and to understand how the body breaks it down over a full year.
Taking part in early-stage research like this helps scientists build the knowledge needed to develop potential new treatments. While it is too early to know what the results will be, the findings will guide future research for the wider ALS community.
Viktiga punkter
- The AURORA study tests an experimental drug called siplizumab in adults newly diagnosed with ALS.
- This is an early Phase 1 study focused primarily on safety and how the drug acts in the body.
- Participation lasts for 52 weeks (approximately one year) and involves regular hospital visits.
- The study aims to understand how siplizumab affects the immune system in people with ALS.
- Joining is entirely voluntary, and you can withdraw at any time.
Vem kan vara berättigad?
This study is looking for adults aged 18 and over who have been newly diagnosed with amyotrophic lateral sclerosis (ALS). Both men and women can take part.
Because this trial looks at the early stages of the condition, it is aimed at people whose symptoms or diagnosis are fairly recent. Doctors will check whether you meet the exact medical criteria, which usually includes being able to travel to study appointments and having a stable overall health status outside of your ALS.
People with other serious medical conditions, certain active infections, or those taking specific medications that interact with the immune system may not be able to join. The trial team will carry out a detailed health check to decide whether the study is a safe option for you.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- You are aged 18 or older.
- You have recently received a diagnosis of ALS (motor neurone disease).
- You are able to travel to a participating hospital clinic for regular visits over 52 weeks.
- You are willing to undergo regular health checks, including blood tests and nerve assessments.
- You do not have other active, severe medical conditions that prevent safe participation.
Vad innebär deltagande?
Taking part in this study lasts for 52 weeks, which is about one year. During this time, you will receive the study medicine, siplizumab, which is usually given under close medical supervision at a specialist hospital clinic.
You will need to attend regular clinic visits throughout the year. At these visits, the study team will carry out safety checks. These include checking your blood pressure, taking blood and urine samples, performing physical and neurological (nerve) examinations, and asking how you are feeling.
The team will monitor you closely after each dose to see if you have any side effects. You will also have scheduled follow-up visits to check your progress and see how long the drug remains in your system.
Potentiella risker och fördelar
Platser (2)
- —ObekräftadSverige
- —ObekräftadTyskland
Vanliga frågor
What is the difference between ALS and MND?
In the UK, motor neurone disease (MND) is an umbrella term for conditions that damage nerve cells. ALS is the most common form of MND.
What is the main goal of a Phase 1 trial?
Phase 1 trials primarily check the safety of a new medicine, see what dose is well tolerated, and find out how the body processes it.
Will I have to pay to take part?
No, clinical trial medicines and study tests are provided free of charge, and trial teams often help cover reasonable travel expenses.
Can I continue seeing my regular neurologist?
Yes, your regular doctors will still manage your general healthcare alongside the trial team.
What happens if I decide to stop taking part?
You are free to leave the trial at any time. Your decision will not alter the standard of care you receive from your healthcare team.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.